Core Insights - Liminatus has announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody aimed at enhancing immune response against tumors [1][2] Group 1: Clinical Trial Details - The Phase 1 study will begin with monotherapy dose escalation to assess safety, tolerability, and pharmacokinetics, followed by combination cohorts with PD-1/PD-L1 therapies [3] - Lung cancer has been selected as the initial focus of the Phase 1 program, addressing the need for improved patient responses in current treatment paradigms [4] - The trial will be led by Dr. Se-Hoon Lee, an expert in immuno-oncology clinical research, and will include translational analyses to characterize immune activity [5] Group 2: Regulatory and Development Plans - The company plans to engage with regulatory authorities as part of its clinical development strategy and aims to be ready to advance the program after completing necessary manufacturing and regulatory preparations [6]